Open session of the standing technical committee of the EUFMD- 2004

Page 104

Appendix 11 Proposals for Phase XIX The main aim of this should be the organisation of two rounds of annual proficiency testing, one in 2005 and the other in 2006. A strong positive sheep and a strong positive pig serum will be prepared from infected but unvaccinated animals along with a negative serum from each species. For each species, a titration series will be prepared and tested by different NSP methods. If acceptable dose response curves are obtained, aliquots of the strong and weak positive sera will be sent to laboratories, for use as NSP standards. Efforts will be made to obtain bulk strong positive sera for the SAT serotypes. If necessary, these could be prepared at the WRLFMD, provided additional funding was made available. These strong positive sera could be distributed in the second year of the study for local titration and use as in-test control sera. In addition, a position paper should be drafted on the purpose and use of secondary standards and intest control sera. Proposal for 2005: 1. Concentrate on proficiency serum panel with serotypes O, A and Asia 1. 2. Aim to provide sheep and pig NSP strong positive sera. 3. Include more sera from vaccinated and infected animals, especially of serotype A. 4. Do not specify particular tests to be used, but rather invite labs to test sera with the methods that they would normally use. 5. Request that interpretation of results be given as if these samples were from animals being examined prior to import (i.e. when serotype/strain of infecting virus would be unknown). 6. Ask EUFMD Secretariat to identify participants and draw up agreement on terms of participation. 7. Make sera available to other participants on request, subject to payment for sera and shipping. 8. Send out serum panel in April 2005. 9. Prepare analysis of results in time for next closed meeting in September 2005. Proposal for 2006: 1. To be finalised at closed meeting in September 2005. 2. Aim to include SAT serotype proficiency sera. 3. Send out serum panel in April 2006. 4. Prepare analysis of results in time for next open meeting in October 2006.

94


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix 82

17min
pages 492-500

Appendix 77

22min
pages 468-476

Appendix 78

25min
pages 477-484

Appendix 79

14min
pages 485-489

Appendix 81

1min
page 491

Appendix 80

1min
page 490

Appendix 76

12min
pages 464-467

Appendix 75

1min
page 463

Appendix 64

10min
pages 412-414

Appendix 72

13min
pages 455-460

Appendix 73

1min
page 461

Appendix 65

1min
page 415

Appendix 67

1min
page 424

Appendix 63

34min
pages 401-411

Appendix 62

2min
page 400

Appendix 54

8min
pages 361-363

Appendix 61

15min
pages 394-399

Appendix 55

11min
pages 364-366

Appendix 59

1min
page 385

Appendix 60

20min
pages 386-393

Appendix 56

1min
page 367

Appendix 42

21min
pages 270-276

Appendix 52

10min
pages 350-352

Appendix 50

21min
pages 330-339

Appendix 46

2min
page 307

Appendix 37

7min
pages 241-243

Appendix 38

7min
pages 244-246

Appendix 41

2min
page 269

Appendix 40

15min
pages 255-268

Appendix 36

16min
pages 236-240

Appendix 35

15min
pages 231-235

Appendix 34

25min
pages 224-230

Appendix 28

2min
page 198

Appendix 31

10min
pages 212-215

Appendix 29

16min
pages 199-203

Appendix 33

3min
pages 221-223

Appendix 27

1min
page 197

Appendix 26

27min
pages 188-196

Appendix 25

12min
pages 182-187

Appendix 23

8min
pages 168-171

Appendix 22

28min
pages 158-167

Appendix 15

2min
page 113

Appendix 16

7min
pages 114-116

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

4min
pages 144-145

Appendix 19

18min
pages 136-143

Appendix 14

4min
page 112

Appendix 13

10min
pages 107-111

Appendix 5

2min
page 64

Appendix 12

9min
pages 104-106

Appendix 3

9min
pages 47-49

Appendix 4

26min
pages 50-63

Appendix 8

12min
pages 77-80

Appendix 2

8min
pages 43-46

Open Session

6min
pages 39-42

Closed Session

2min
pages 37-38

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

3min
page 33

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

3min
page 36

Item 14 – Regulatory compliance

2min
page 35

Item 10 – International issues

3min
page 32

Item 9 – Novel vaccines

3min
page 31

Item 7 – Optimisation of conventional vaccines

3min
page 29

Item 4 – Managing diagnostic demands

3min
page 27

Item 8 – Regulatory issues affecting FMD vacine selection and use

3min
page 30

Item 3 – Transmission and its control

3min
page 26

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

3min
page 16

Item 1 – Recent findings in molecular epidemiology of FMDV

3min
page 24

Item 2 – Surveillance: for what purpose and how much is enough?

3min
page 25

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection

3min
page 20
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
Open session of the standing technical committee of the EUFMD- 2004 by EuFMD - Issuu